Estudio de utilización de antimicrobianos en un servicio de cirugía general tras modificaciones en la guía farmacoterapéutica
Contenido principal del artículo
Resumen
Palabras clave:
Descargas
Detalles del artículo
Citas
Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:1-12.
Clatworthy AE, Pierson E, Hunget DT. Targeting virulence: a new paradigm for antimicrobial therapy. Nat Chem Biol. 2007;3:541-8.
Gilbert DN, Guidos RJ, Boucher HW, et al. The 10 × ′20 initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis 2010;50:1081-1083.
- Guirao X, Arias J, Badia JM, García-Rodriguez JA, Mensa J, Álvarez-Lerma F et al. Recomendaciones en el tratamiento antibiótico empírico de la infección intraabdominal. Cir Esp. 2010; 87 (2): 63-81.
Infectious Diseases Society of America (IDSA). Combating Antimicrobial Resistance: Policy Recommendations to Save Lives. Clin Infect Dis. 2011;52(Supplement 5):S397-S428.
Kuster SP, Ruef C, Ledergerber B, Hinterman A, Deplazes C, Neuber L et al: Quantitative Antibiotic Use in Hospitals: Comparison of measurements, literature review, and recommendations for a standard of reporting. Infection 2008 (36) nº6: 549-559.
Lipsitch M, Samore MH. Antimicrobial use and antimicrobial resistance: a population perspective. Emerging Infect Dis. 2002;8:347-54.
Martínez-Martínez L, Calvo J. Development of resistance to antibiotic drugs: causes, consequences, and importance to the public health system. Enferm Infecc Microbiol Clin. 2010;28(Supl. 4):4-9.
WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2010. 13th ed. Oslo: Norwegian Institute of Public Health; 2010.